260 related articles for article (PubMed ID: 30211824)
21. The glucagon-like peptide-1 receptor agonist liraglutide improves hypoxia-induced pulmonary hypertension in mice partly via normalization of reduced ET(B) receptor expression.
Honda J; Kimura T; Sakai S; Maruyama H; Tajiri K; Murakoshi N; Homma S; Miyauchi T; Aonuma K
Physiol Res; 2018 Jun; 67(Suppl 1):S175-S184. PubMed ID: 29947538
[TBL] [Abstract][Full Text] [Related]
22. Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
Foer D; Amin T; Nagai J; Tani Y; Feng C; Liu T; Newcomb DC; Lai J; Hayashi H; Snyder WE; McGill A; Lin A; Laidlaw TM; Niswender KD; Boyce JA; Cahill KN
J Immunol; 2023 Dec; 211(12):1806-1813. PubMed ID: 37870292
[TBL] [Abstract][Full Text] [Related]
23. Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway.
Feng Y; Wang L; Ma X; Yang X; Don O; Chen X; Qu J; Song Y
Stem Cell Res Ther; 2020 Jan; 11(1):2. PubMed ID: 31900217
[TBL] [Abstract][Full Text] [Related]
24. Transplantation tolerance prevents cardiac allograft vasculopathy in major histocompatibility complex class I-disparate miniature swine.
Madsen JC; Yamada K; Allan JS; Choo JK; Erhorn AE; Pins MR; Vesga L; Slisz JK; Sachs DH
Transplantation; 1998 Feb; 65(3):304-13. PubMed ID: 9484744
[TBL] [Abstract][Full Text] [Related]
25. Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function.
Xu J; Wei G; Wang J; Zhu J; Yu M; Zeng X; Wang H; Xie W; Kong H
Lab Invest; 2019 Apr; 99(4):577-587. PubMed ID: 30659271
[TBL] [Abstract][Full Text] [Related]
26. Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice.
Tsai TH; Lee CH; Cheng CI; Fang YN; Chung SY; Chen SM; Lin CJ; Wu CJ; Hang CL; Chen WY
Cells; 2019 Jun; 8(6):. PubMed ID: 31207939
[TBL] [Abstract][Full Text] [Related]
27. Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT 2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart.
Zhang LH; Pang XF; Bai F; Wang NP; Shah AI; McKallip RJ; Li XW; Wang X; Zhao ZQ
Cardiovasc Drugs Ther; 2015 Jun; 29(3):243-55. PubMed ID: 25994830
[TBL] [Abstract][Full Text] [Related]
28. Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.
Shi L; Ji Y; Jiang X; Zhou L; Xu Y; Li Y; Jiang W; Meng P; Liu X
Cardiovasc Diabetol; 2015 Feb; 14():18. PubMed ID: 25855361
[TBL] [Abstract][Full Text] [Related]
29. GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice.
Kumari P; Nakata M; Zhang BY; Otgon-Uul Z; Yada T
Biochem Biophys Res Commun; 2018 May; 499(3):618-625. PubMed ID: 29601817
[TBL] [Abstract][Full Text] [Related]
30. [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].
Haluzík M; Trachta P; Mráz M
Vnitr Lek; 2015; 61(7-8):635-40. PubMed ID: 26375689
[TBL] [Abstract][Full Text] [Related]
31. Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation.
Moschovaki Filippidou F; Kirsch AH; Thelen M; Kétszeri M; Artinger K; Aringer I; Schabhüttl C; Mooslechner AA; Frauscher B; Pollheimer M; Niedrist T; Meinitzer A; Drucker DJ; Pieber TR; Eller P; Rosenkranz AR; Heinemann A; Eller K
Am J Pathol; 2020 Feb; 190(2):400-411. PubMed ID: 31759969
[TBL] [Abstract][Full Text] [Related]
32. The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy.
Almutairi M; Gopal K; Greenwell AA; Young A; Gill R; Aburasayn H; Al Batran R; Chahade JJ; Gandhi M; Eaton F; Mailloux RJ; Ussher JR
Can J Cardiol; 2021 Jan; 37(1):140-150. PubMed ID: 32640211
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients.
Daly KP; Stack M; Eisenga MF; Keane JF; Zurakowski D; Blume ED; Briscoe DM
J Heart Lung Transplant; 2017 Apr; 36(4):434-442. PubMed ID: 27865734
[TBL] [Abstract][Full Text] [Related]
34. GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation.
Bang-Berthelsen CH; Holm TL; Pyke C; Simonsen L; Søkilde R; Pociot F; Heller RS; Folkersen L; Kvist PH; Jackerott M; Fleckner J; Vilién M; Knudsen LB; Heding A; Frederiksen KS
Inflamm Bowel Dis; 2016 Sep; 22(9):2078-97. PubMed ID: 27542128
[TBL] [Abstract][Full Text] [Related]
35. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
Hernández C; Bogdanov P; Corraliza L; García-Ramírez M; Solà-Adell C; Arranz JA; Arroba AI; Valverde AM; Simó R
Diabetes; 2016 Jan; 65(1):172-87. PubMed ID: 26384381
[TBL] [Abstract][Full Text] [Related]
36. Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats.
Xu J; Wang J; Cheng Y; Li X; He M; Zhu J; Han H; Wei G; Kong H; Xie W; Wang H; Zuo X
Biomed Res Int; 2018; 2018():1864107. PubMed ID: 29607314
[TBL] [Abstract][Full Text] [Related]
37. The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension.
Younes ST; Maeda KJ; Sasser J; Ryan MJ
Am J Physiol Heart Circ Physiol; 2020 Jan; 318(1):H72-H77. PubMed ID: 31729903
[TBL] [Abstract][Full Text] [Related]
38. Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein.
Zhou W; Shao W; Zhang Y; Liu D; Liu M; Jin T
Am J Physiol Endocrinol Metab; 2020 Sep; 319(3):E568-E578. PubMed ID: 32723174
[TBL] [Abstract][Full Text] [Related]
39. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
Al Batran R; Almutairi M; Ussher JR
Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
[TBL] [Abstract][Full Text] [Related]
40. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
Noyan-Ashraf MH; Shikatani EA; Schuiki I; Mukovozov I; Wu J; Li RK; Volchuk A; Robinson LA; Billia F; Drucker DJ; Husain M
Circulation; 2013 Jan; 127(1):74-85. PubMed ID: 23186644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
